Pepped Up Over Chronic FatigueBy
We aren't biotech investors, "but we've bought into Hemispherx BioPharma--the only biotech in our portfolio," says Richard Sinise of Kennedy Capital Management in St. Louis, which manages some $1.5 billion. Sinise isn't the only believer. Investors Larry Tisch and Gerry Tsai also are stakeholders in the young company. What's so hot about Hemispherx (HEMX)? The stock sure hasn't been on a roll: Now at 21/2, it has traded between 2 and 4 since July.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.